Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Breast Cancer

  Free Subscription


Articles published in Nat Rev Clin Oncol

Retrieve available abstracts of 13 articles:
HTML format



Single Articles


    March 2024
  1. KONTOS D
    The promise of AI in personalized breast cancer screening: are we there yet?
    Nat Rev Clin Oncol. 2024 Mar 12. doi: 10.1038/s41571-024-00877.
    PubMed    


    January 2024
  2. MARRA A, Chandarlapaty S, Modi S
    Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives.
    Nat Rev Clin Oncol. 2024 Jan 8. doi: 10.1038/s41571-023-00849.
    PubMed     Abstract available


    December 2023
  3. BERTON GIACHETTI PPM, Curigliano G
    Pyrotinib in combination with first-line trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer: a new therapeutic option?
    Nat Rev Clin Oncol. 2023 Dec 19. doi: 10.1038/s41571-023-00854.
    PubMed    


  4. MORRISON L, Loibl S, Turner NC
    The CDK4/6 inhibitor revolution - a game-changing era for breast cancer treatment.
    Nat Rev Clin Oncol. 2023 Dec 11. doi: 10.1038/s41571-023-00840.
    PubMed     Abstract available


    November 2023
  5. SIDAWAY P
    Sacituzumab govitecan improves OS in heavily pretreated patients.
    Nat Rev Clin Oncol. 2023;20:734.
    PubMed    


    October 2023
  6. ARECCO L, Lambertini M
    Safety of interrupting adjuvant endocrine therapy to conceive: early data are POSITIVE.
    Nat Rev Clin Oncol. 2023;20:662-663.
    PubMed    


    July 2023
  7. SIDAWAY P
    T-DXd is effective after T-DM1.
    Nat Rev Clin Oncol. 2023;20:426.
    PubMed    


    February 2023
  8. O'LEARY B
    PADA-1 trial: ESR1 mutations in plasma ctDNA guide treatment switching.
    Nat Rev Clin Oncol. 2023;20:67-68.
    PubMed    


    October 2022
  9. AGOSTINETTO E, Gligorov J, Piccart M
    Systemic therapy for early-stage breast cancer: learning from the past to build the future.
    Nat Rev Clin Oncol. 2022 Oct 17. pii: 10.1038/s41571-022-00687.
    PubMed     Abstract available


    July 2022
  10. VASAN N, Cantley LC
    At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy.
    Nat Rev Clin Oncol. 2022;19:471-485.
    PubMed     Abstract available


    April 2022
  11. SIDAWAY P
    Pembrolizumab improves EFS in TNBC.
    Nat Rev Clin Oncol. 2022;19:220.
    PubMed    


    March 2022
  12. SOUTHEY MC, Dugue PA
    Improving breast cancer risk prediction with epigenetic risk factors.
    Nat Rev Clin Oncol. 2022 Mar 29. pii: 10.1038/s41571-022-00622.
    PubMed    


    November 2021
  13. BIANCHINI G, De Angelis C, Licata L, Gianni L, et al
    Treatment landscape of triple-negative breast cancer - expanded options, evolving needs.
    Nat Rev Clin Oncol. 2021 Nov 9. pii: 10.1038/s41571-021-00565.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.